Biofrontera Inc. BFRI
We are a United States based biopharmaceutical company engaging in the development,
manufacturing, and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic
therapy ("PDT"). The Company's products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamp series
(together, the "RhodoLED Lamps"), are used for the treatment of actinic keratosis ("AK"), a common skin condition
Last close
0.79
2026-10-23
Market cap
$11.7M
2026-06-30 share count
52-week range
0.55 - 1.66
Valuation FY2025 figures against the last close
P/S0.3x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-1.04
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $41.7M | $37.3M | $34.1M | $28.7M | $24.0M | $18.8M | — |
| R&D | $3.7M | $2.1M | $77.0K | — | — | — | — |
| SG&A | $37.8M | $33.8M | $18.5M | $35.1M | $36.5M | $17.7M | — |
| Total operating expenses | $53.1M | $54.5M | $56.7M | $47.3M | $49.3M | $28.5M | — |
| Operating income | -$11.3M | -$17.2M | -$22.7M | -$18.6M | -$25.2M | -$9.6M | — |
| Interest expense | — | — | $220.0K | $12.0K | $344.0K | $2.9M | — |
| Pre-tax income | -$10.5M | -$17.7M | -$20.1M | -$608.0K | -$37.7M | -$10.9M | — |
| Income tax | $25.0K | $22.0K | $14.0K | $32.0K | $56.0K | $64.0K | — |
| Net income | -$10.5M | -$17.8M | -$20.1M | -$640.0K | -$37.7M | -$11.0M | — |
| EPS, basic | -1.04 | -3.22 | -13.02 | -0.61 | -85.63 | — | — |
| EPS, diluted | -1.04 | -3.22 | -13.02 | -0.61 | -4.28 | -479.48 | — |
| Shares, diluted (wtd. avg.) | 10.2M | 5.5M | 1.5M | 1.1M | 440,412 | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $6.4M | $5.9M | $1.3M | $17.2M | $24.5M | $8.1M | — |
| Receivables | — | — | — | $3.7M | $3.8M | — | — |
| Inventory | $1.4M | $6.6M | $10.9M | $7.2M | $4.5M | $7.1M | — |
| Total current assets | $18.1M | $20.7M | $23.1M | $43.1M | $46.4M | $19.6M | — |
| Property, plant and equipment | $2.2M | $80.0K | $134.0K | $204.0K | $267.0K | $370.0K | — |
| Other intangibles | $2.6M | $35.0K | $2.6M | $3.0M | $3.5M | $3.9M | — |
| Total assets | $28.6M | $22.1M | $27.9M | $50.9M | $53.2M | $24.1M | — |
| Accounts payable | — | — | — | $1.3M | $658.0K | $176.0K | — |
| Short-term debt | — | — | $3.9M | — | — | — | — |
| Total current liabilities | $11.9M | $12.0M | $18.1M | $20.9M | $13.8M | $4.4M | — |
| Total liabilities | $18.1M | $17.7M | $23.1M | $27.0M | $41.9M | $18.3M | — |
| Retained earnings | -$127.9M | -$117.4M | -$99.7M | -$79.5M | -$78.9M | -$41.2M | — |
| Total equity | $10.5M | $4.4M | $4.8M | $23.9M | $11.3M | $5.8M | -$30.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$13.4M | -$10.3M | -$24.9M | -$16.2M | -$26.7M | -$12.4M | — |
| Depreciation and amortisation | $138.0K | $421.0K | $86.0K | $101.0K | $122.0K | $144.0K | — |
| Stock-based compensation | $951.0K | $1.0M | $1.0M | $1.9M | $129.0K | — | — |
| Capital expenditure | $2.0K | $10.0K | $5.0K | $38.0K | — | — | — |
| Investing cash flow | $3.0M | -$3.0K | $619.0K | -$5.2M | -$11.0K | — | — |
| Financing cash flow | $10.8M | $14.8M | $8.4M | $14.0M | $43.2M | $13.2M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-034251.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $18.8M | $24.0M | $28.7M | $34.1M | $37.3M | $41.7M |
| Gross profit | — | — | — | — | — | — | — |
| Net income | — | -$11.0M | -$37.7M | -$640.0K | -$20.1M | -$17.8M | -$10.5M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Regulation FD disclosure Item 7.01
- Results announced Item 2.02
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Results announced Item 2.02
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |